Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Increasing evidence that the risks of rhAPC may outweigh its benefits.

Eichacker PQ, Natanson C.

Intensive Care Med. 2007 Mar;33(3):396-9. No abstract available.

PMID:
17325833
2.

Risks and benefits of activated protein C treatment for severe sepsis.

Warren HS, Suffredini AF, Eichacker PQ, Munford RS.

N Engl J Med. 2002 Sep 26;347(13):1027-30. No abstract available.

PMID:
12324562
3.

Adverse events and clinical outcome associated with drotrecogin alfa-activated: a single-center experience of 498 patients over 8 years.

Boyle A, McKenzie C, Yassin S, McLuckie A, Wyncoll D.

J Crit Care. 2012 Jun;27(3):320.e7-12. doi: 10.1016/j.jcrc.2011.07.004.

PMID:
22172792
4.

Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C.

Crit Care Med. 2005 Oct;33(10):2426-8. No abstract available.

PMID:
16215410
5.

Recombinant human activated protein C, package labeling, and hemorrhage risks.

Sweeney DA, Natanson C, Eichacker PQ.

Crit Care Med. 2009 Jan;37(1):327-9. doi: 10.1097/CCM.0b013e3181935102. No abstract available.

PMID:
19112285
6.

[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].

Rustige J.

Dtsch Med Wochenschr. 2004 Jul 30;129(31-32):1698; author reply 1699-70. German. No abstract available.

PMID:
15273923
7.

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

Kanji S, Perreault MM, Chant C, Williamson D, Burry L.

Intensive Care Med. 2007 Mar;33(3):517-23.

PMID:
17325837
8.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group..

N Engl J Med. 2005 Sep 29;353(13):1332-41.

9.

Is there increasing evidence that the risks of rhAPC may outweigh its benefits?

Plataki M, Vaporidi K, Georgopoulos D.

Intensive Care Med. 2007 Aug;33(8):1485-6; author reply 1489. No abstract available.

PMID:
17563880
10.

Drotrecogin alfa: excess mortality in the least severely ill patients.

[No authors listed]

Prescrire Int. 2005 Aug;14(78):145. No abstract available.

PMID:
16108104
11.

Activated protein C: do more survive?

Macias WL.

Intensive Care Med. 2006 Apr;32(4):605-7; author reply 610-2. No abstract available.

PMID:
16508756
12.

Activated protein C: do more survive?

Ridley S.

Intensive Care Med. 2006 Apr;32(4):608; author reply 610-2. No abstract available.

PMID:
16508755
13.

Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.

Farmer JC.

Crit Care Med. 2005 Oct;33(10):2428-31. No abstract available.

PMID:
16215411
14.

[Severe sepsis treated with activated protein C].

Frøyshov S, Jacobsen D, Bjertnaes L, Flaatten H.

Tidsskr Nor Laegeforen. 2004 Mar 18;124(6):779-81. Norwegian.

15.

Assessing the use of activated protein C in the treatment of severe sepsis.

Siegel JP.

N Engl J Med. 2002 Sep 26;347(13):1030-4. No abstract available.

PMID:
12324563
16.

[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].

Heslet L, Nielsen JD, Schierbeck J, Andersen JS.

Ugeskr Laeger. 2004 Mar 8;166(11):997-1002. Review. Danish. No abstract available.

PMID:
15049234
17.
18.

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

Crit Care. 2003 Apr;7(2):155-63. Review.

19.

[Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].

Girbes AR, Polderman KH, Beishuizen A, van Zanten AR, Schultz MJ.

Ned Tijdschr Geneeskd. 2006 Jun 3;150(22):1265-6; author reply 1266. Dutch. No abstract available.

PMID:
16796179
20.

Recombinant human activated protein C sentenced to the death of a thousand cuts?

O'Brien JM.

Crit Care Med. 2007 Jun;35(6):1609-10. No abstract available.

PMID:
17522532
Items per page

Supplemental Content

Support Center